•	BioLineRx Initiates Phase 2b Clinical Trials of BL-1020, a GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia June 12, 2008 BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, announced today the initiation of a Phase 2b clinical trial to assess the efficacy, safety and tolerability of BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia.
•	BioLineRx to Present at BioCentury's Future Leaders in the Biotech Industry Conference 2008 March 24, 2008 BioLineRx Ltd. (TASE: BLRX) announced today that Morris C. Laster, MD, CEO will present a company overview at BioCentury's Future Leaders in the Biotech Industry Conference 2008 on Thursday, March 27, 2008, at 11:00 AM EDT at the Millennium Broadway Hotel & Conference Center in New York City.
•	First Patient Successfully Undergoes Breakthrough Treatment for Acute Myocardial Infarction Developed by BioLineRx March 24, 2008 BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced that the first patient treated with BL-1040 was released from the Department of Cardiology at the University of Heidelberg in Germany following treatment with no apparent adverse effects.
•	BioLineRx to Present at BIO CEO & Investor Conference 2008 February 6, 2008 BioLineRx Ltd. (TASE: BLRX) announced today that Yuri Shoshan, Vice President of Finance and Corporate Development, will present a company overview and recently announced data from a phase 2a trial of BL-1020, a GABA-enhanced antipsychotic, at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008, at 10:15 AM ET at The Waldorf-Astoria Hotel in New York City.
•	BioLineRx Announces Positive Results from Phase 2a Trial of BL-1020, a GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia February 4, 2008 BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced positive results from a Phase 2a trial of BL-1020, a GABA-enhanced antipsychotic. BL-1020 showed statistically significant efficacy with no significant change in weight and no increase in extrapyramidal symptoms at study completion.
•	BioLineRx Presents Pre-Clinical Data Demonstrating that BL-1021 is Safe and Effective in Treating Neuropathic Pain January 28, 2008 BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced the presentation of data from pre-clinical trials of BL-1021 at the Isranalytica meeting 2008 held in Tel Aviv, Israel, on January 22-23, 2008. Recent pre-clinical trials demonstrated that BL-1021 was safe and effective in pre-clinical testing for the treatment of neuropathic pain.
•	BioLineRx Announces Presentation of Pre-Clinical Data Demonstrating that BL-2030 Reduces Tumor Growth and Prevents Metastasis in Model of Prostate Cancer December 19, 2007 BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, announced today that data from pre-clinical trials of BL-2030 were presented at the Inflammation-Induced Cancer meeting 2007 held in Jerusalem and the Western Galilee, Israel, on December 16-19, 2007.
•	BioLineRx In-Licenses Novel Formulation BL-5010 for the Non-Surgical Removal of Skin Lesions Dec. 10, 2007 BioLineRx Ltd. (TASE: BLRX), a clinical stage drug development company, today announced that it has signed a worldwide exclusive license agreement with Innovative Pharmaceutical Concepts, Ltd., a privately held company, for the development and commercialization of BL-5010, a novel formulation for the non-surgical removal of skin lesions.
•	BioLineRx In-Licenses Anti-Cancer Compound BL-4060 Nov. 15, 2007 BioLineRx Ltd. (TASE: BLRX) today announced that it has signed a worldwide exclusive license agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, and Hadasit, the technology transfer company of Hadassah medical organization, for the development and commercialization of BL-4060, a small molecule drug candidate for the treatment of cancer.
•	BioLineRx Presents BL-1040 Data at the American Heart Association Scientific Sessions 2007 November 6, 2007 BioLineRx Ltd. (TASE: BLRX) announced today that data from pre-clinical trials of BL-1040, a resorbable implant to treat acute myocardial infarction, was presented at the American Heart Association (AHA) Scientific Sessions 2007 held in Orlando, Florida, November 4-7, 2007.
•	BioLineRx to Present at Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference October 31, 2007 BioLineRx Ltd. (TASE: BLRX) announced today that Morris C. Laster, MD, chief executive officer, will present an overview of BioLineRx at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Wednesday, November 7, 2007, at 8:30 AM at the New York Palace Hotel in New York.
•	BioLineRx Announces Positive Results from Phase 2a Interim Trial Analysis of BL-1020 for the Treatment of Patients with Schizophrenia October 29, 2007 BioLineRx Ltd. (TASE: BLRX), today announced positive interim results from an ongoing Phase 2 trial of BL-1020, a GABA enhanced antipsychotic. The study is an open-label, multi-center, 6-week trial conducted in hospitalized patients with treatment resistant schizophrenia, in which BL-1020 showed statistically significant efficacy with minimal side effects.
•	BioLineRx Presents BL-1040 Data at the Transcatheter Cardiovascular Therapeutics Conference October 22 Israel’s leading drug development company, announced today that data from pre-clinical trials of BL-1040, a resorbable implant to treat acute myocardial infarction, was presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C.
•	BioLineRx Investigates Raising Additional Capital and Listing of Ordinary Shares for Trading on the NASDAQ Stock Market October 16, 2007 BioLineRx Ltd. (TASE: BLRX), today announced that its Board of Directors has directed the Company’s management to investigate various alternatives for raising additional capital and the listing of the Company's ordinary shares for trading on The NASDAQ Stock Market (“NASDAQ”), in each case subject to market conditions and other considerations.
•	BioLineRx In-Licenses Novel Peptide BL-4050 for the Treatment of Cancer Oct. 1, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, today announced that it has signed a worldwide exclusive license agreement with Yeda Research and Development Company Ltd., the technology transfer company of the Weizmann Institute of Science, for the development and commercialization of BL-4050, a novel peptide for the treatment of cancer.
•	BioLineRx In-Licenses Novel Drug for the Treatment of Acute Kidney Injury August 27, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, today announced that it has signed a worldwide exclusive license agreement with Gene Vector Technologies Ltd. for the development and commercialization of BL-4040, a novel drug for the treatment of acute kidney injury (AKI).
•	BioLineRx Adds Three Industry Experts to its Board of Directors August 7, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company announced today that Tamar Howson, Gil Bianco and Ilan Leviteh have been appointed to the Company's board of directors.
•	BioLineRx Initiates Phase II Trial of BL-1020, a First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia July 25, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, today announced the initiation of a Phase II clinical trial on schizophrenic patients for the maximal tolerated dose determination of BL-1020. BL-1020 is a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.
•	BioLineRx and University of Illinois Enter Licensing Agreement to Develop Apoptosis Agent to Treat Cancer July 23, 2007 BioLineRx Ltd. (TASE: BLRX), Israel's leading drug development company, and the University of Illinois at Urbana-Champaign announced today that they have entered into an exclusive worldwide licensing agreement for the research, development and commercialization of BL-4030, a small molecule for the treatment of cancer.
•	BioLineRx Announces Results of Clinical Receptor-Occupancy Study of BL-1020, a First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia July 16, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, announced today the successful completion of a study determining the clinical binding properties of BL-1020 to the dopamine receptors in the human brain. The study has shown that BL-1020, the first GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia, blocks dopamine receptors in the human brain, providing direct evidence of antipsychotic efficacy.
•	BioLineRx Submits Application to Begin Pilot (Phase 1/2) Clinical Trials of BL-1040 to Treat Damaged Cardiac Tissue Following Acute MI June 6, 2007 BioLineRx Ltd. (TASE: BLRX), Israel's leading drug development company, announced today that it has submitted a request to a European regulatory agency to begin pilot (Phase 1/2) clinical trials of BL-1040, an absorbable implant to treat cardiac tissue damaged as the result of an acute myocardial infarction (heart attack or MI).
•	BioLineRx Introduces Early Development Program - Program funded by $6 million grant from Pan Atlantic Group and BioLineRx - June 5, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company announced today the launch of its Early Development Program (EDP), a new strategic initiative to provide funding for early stage research and development of innovative therapeutics that have not yet achieved in-vivo proof of concept.
•	BioLineRx Presents Data from Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference May 22, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company reported today data from its Phase I trial of BL-1020, the first GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia.
•	BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences May 17, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, announced today that abstracts containing data from its successfully completed phase I clinical trails of BL-1020, first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, have been accepted for poster presentations at three leading scientific conferences.
•	BioLineRx Initiates a Clinical Receptor-Occupancy Study of BL-1020, First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia May 16, 2007 - Phase II trial expected to begin on schedule in June 2007 -
•	BioLineRx In-Licenses Two Additional Drug Candidates March 26, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, today announced that it has signed in-license agreements to develop and commercialize two new therapeutic candidates: BL-3040, a small molecule for the treatment of estrogen-regulated malignancies and osteoporosis; and BL-3050, a protein complex for the treatment of atherosclerosis.
•	BioLineRx In-Licenses Novel Peptide for the Treatment of Inflammatory Diseases March 21, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, today announced that it has signed a worldwide exclusive license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, one of the world's leading technology transfer companies, and Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-4020, a novel peptide for the treatment of inflammatory diseases.
•	BioLineRx In-Licenses Novel Drug Delivery System for the Treatment of Solid Tumors and Bone Infections March 12, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, today announced that it has signed worldwide exclusive license agreements with PolyGene Ltd. and Efrat BioPolymers Ltd. for the development and commercialization of their proprietary polymer drug delivery system designed to improve the efficacy, safety and ease of administration of a variety of drugs.
•	BioLineRx Presents Data on BL-1040 Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality March 7, 2007 BioLineRx Ltd. (TASE: BLRX), Israel’s leading drug development company, reported today pre-clinical data from trials of BL-1040 demonstrating that BL-1040 is effective in preventing deterioration of the myocardium after a myocardial infarction (MI), thereby reducing left ventricle dilatation and eventual heart failure in a pig model.
•	BioLineRx Successfully Completes Phase 1 Clinical Trials of BL-1020, First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia February 13, 2007 - Compound was well tolerated and showed preliminary evidence of clinical activity - - Company expected to initiate Phase 2 for BL-1020 in the second quarter of 2007 -
•	BioLineRx to Present at BIO CEO & Investor Conference 2007 February 8, 2007 BioLineRx Ltd. (TASE: BLRX), Israel's leading drug development company, announced today that Morris C. Laster, MD, CEO, will present a company overview at the BIO CEO & Investor Conference 2007 on Tuesday, February 13, 2007, at 4:30 PM ET at The Waldorf=Astoria Hotel in New York City.
•	BioLineRx Announces Pricing of Initial Public Offering on Tel Aviv Stock Exchange Raising US $50 Million February 7, 2007 BioLineRx Ltd., Israel’s leading drug development company, announced today the pricing of its Initial Public Offering (IPO) of 28,690,000 shares of common stock at approximately $1.74 per share. The total amount raised in the IPO was $50 million. This marks the largest IPO on the Tel Aviv Stock Exchange (TASE) of a biomedical company. BioLineRx’s common stock will be listed on the TASE under the trading symbol “BLRX.”
•	BioLineRx In-Licenses Novel Antisense Drug for the Treatment of Inflammatory Diseases September 8, 2006 BioLineRx, Ltd., Israel’s leading drug development company, announced today that it has signed an exclusive worldwide license agreement with B.G. Negev (BGN) Technologies Ltd., the technology transfer company of Ben-Gurion University of the Negev, and Mor Research Applications, Ltd., the Technology Transfer Office of Clalit Health Services for the development and commercialization of BL-3030, a novel antisense drug for the treatment of inflammatory diseases.
•	BioLineRx In-Licenses Novel Orally-Available Peptide for the Treatment of Obesity July 17, 2006 BioLineRx, Ltd., Israel’s leading drug development company, announced today that it has signed an exclusive worldwide licensing agreement with Yissum, the technology transfer company of the Hebrew University of Jerusalem, for the development and commercialization of BL-3020, a novel orally-available peptide for the treatment of obesity. Financial terms of the license were not disclosed.
•	BioLineRx In-Licenses BL-3010 from Gevys Pharmaceuticals for the Treatment of Pain and Plans to Initiate Phase I/II Trial May 25, 2006 BioLineRx, Ltd., Israel’s leading drug development company, today announced that it has signed an exclusive worldwide licensing agreement with Gevys Pharmaceuticals Ltd. for the development and commercialization of BL-3010, a novel approach for the treatment of acute and chronic pain.
•	BioLineRx to Present BL-1020, First in Class Small Molecule for the Treatment of Schizophrenia, at the American Psychiatric Association Annual Meeting May 18, 2006 BioLineRx Ltd., Israel’s leading drug development company, will present a poster regarding BL-1020, its lead compound currently being studied as a treatment for schizophrenia, at two leading scientific psychiatric meetings: the American Psychiatric Association Annual Meeting, May 20-25, Toronto; and the Society of Biological Psychiatry Annual Scientific Program and Convention, May 18-20, Toronto.
•	BioLineRx Named a Winner of the Red Herring 100 Europe Award May 8, 2006 BioLineRx Ltd., Israel’s leading drug development company, today announced that it has been selected by Red Herring as one of the top 100 private companies in Europe (including Israel) that play a leading role in innovation and technology.
•	BioLineRx Initiates Phase 1 Clinical Trials of BL-1020, First in Class Small Molecule for the Treatment of Schizophrenia April 10, 2006 BioLineRx Ltd., Israel’s leading drug development company, announced today the initiation of a randomized, placebo-controlled Phase 1 clinical trial to evaluate the safety and determine the pharmacokinetic profile of BL-1020, a first in class, proprietary small molecule for the treatment of schizophrenia.
•	BioLineRx In-Licenses Two Additional Drug Candidates for Treatment of PVD and Bacterial Infection January 16, 2006 BioLineRx, Ltd., Israel’s leading specialized drug development company, today announced that it has signed two license agreements for the development and commercialization of BL-2050, for the treatment of peripheral vascular disease (PVD) and BL-2060, a novel antibiotic.
•	BioLineRx Raises an Additional $9 Million and Advances Pipeline of Drug Candidates toward Clinical Trials September 27, 2005 BioLineRx, Israel’s leading specialized drug development company, today announced that current investors Giza Venture Capital, Pitango Venture Capital and Teva Pharmaceuticals Industries Ltd. have committed an additional $9 million in funding to the company. The $9 million follow-on investment is on top of the original founders’ commitment of approximately $14 million, which also included Hadasit, Star Ventures, and the Jerusalem Development Authority, and is supplemented by the $21 million Israeli National Biotech Initiative grant that BioLineRx received in November of last year.
•	BioLineRx's BL-1020 Approach for Innovative Schizophrenia Treatment Validated By National Institutes of Mental Health Study September 22, 2005 BioLineRx Ltd., Israel’s leading drug development company, today confirmed that its patented BL-1020 compound for the treatment of schizophrenia specifically meets the recommendations and guidelines published by the NIMH following the results of the groundbreaking Clinical Antipsychotic Trials of Intervention Efficacy (CATIE) study
•	BioLineRx Expands Drug Pipeline with Two Innovative Pre-Clinical Candidates for Treatment of Metabolic Syndrome and Cancer June 20, 2005 BioLineRx Ltd., Israel’s leading specialized drug development company, today announced that it has signed in-license agreements to develop and commercialize two new therapeutic candidates. The two compounds are designated BL-2030, a soluble receptor that targets cancer cells that will be developed first for the treatment of prostate cancer, and BL-2040, a small molecule for the treatment of hypertension, obesity, and metabolic syndrome.
•	BioLineRx In-Licenses Novel Technology from Galmed International for the Treatment of Fatty Liver Disease March 13, 2005 BioLineRx Ltd., Israel’s leading specialized drug development company, today announced that it has signed a license agreement for the development and commercialization of BL-1060, a small molecule for the treatment of fatty liver disease.
•	BioLineRx In-Licenses Novel Technology from Ben-Gurion University for the Treatment of Heart Attack Victims January 19, 2005 BioLineRx Ltd., Israel’s leading specialized drug development company, today announced that it has signed an in-license agreement for the development of BL-1040, an injectable scaffold that reduces cardiac damage after heart attack.
•	BioLineRx Expands Drug Pipeline with Three New Pre-Clinical Candidates for Treatment of Cancer, HIV and Inflammatory Bowel Disease January 12, 2005 The three compounds are BL-1030, a small molecule for the treatment of Inflammatory Bowel Disease; BL-1050, a novel HIV therapeutic; and BL-2010, an innovative technology for the treatment of resistant cancer.
•	BioLineRx Awarded Israeli Government Grant of $21 Million for the Development of Innovative Pre-Clinical Drug Candidates December 2, 2004 The Israeli Office of the Chief Scientist yesterday announced the selection of BioLineRx as the sole recipient of a $21 million grant for the development of pre-clinical compounds as part of a special initiative for the advancement of the Israeli Biotech industry.
•	BioLineRx SAB Member Aaron Ciechanover wins Nobel Prize in Chemistry October 6, 2004 Nobel in Chemistry Goes to 2 Israelis, 1 American
•	BioLineRx Announces Completion of Management Team June 13, 2004 Dr. Kinneret Savitsky Joins Executive Leadership as Vice President of Drug Development
•	BioLineRx In-Licenses Innovative Platform for the Treatment of Neurological Disorders from Tel Aviv and Bar Ilan Universities May 6, 2004 Implements in-licensing strategy and builds proprietary drug pipeline
•	Star Ventures and Yehuda Zisapel Join BioLineRx as Founding Investors May 5, 2004 Additional investment secures BioLineRx as one of Israel’s key developers of innovative drugs